A randomised controlled trial of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDITOF-MS) versus conventional microbiological methods for identifying pathogens: Impact on optimal antimicrobial therapy of invasive bacterial and fungal infections in Vietnam. by Nadjm, Behzad et al.
ARTICLE IN PRESS 
JID: YJINF [m5G; April 3, 2019;13:23 ] 
Journal of Infection xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Journal of Infection 
journal homepage: www.elsevier.com/locate/jinf 
A randomised controlled trial of matrix-assisted laser desorption 
ionization-time of ﬂight mass spectrometry (MALDITOF-MS) versus 
conventional microbiological methods for identifying pathogens: 
Impact on optimal antimicrobial therapy of invasive bacterial and 
fungal infections in Vietnam 
Behzad Nadjm a , b , 1 , ∗, Vu Quoc Dat a , c , 1 , James I. Campbell a , b , Vu Tien Viet Dung a , 
Alessandro Torre a , Nguyen Thi Cam Tu a , Ninh Thi Thanh Van a , Dao Tuyet Trinh d , 
Nguyen Phu Huong Lan e , Nguyen Vu Trung d , Nguyen Thi Thuy Hang d , Le Thi Hoi d , 
Stephen Baker a , b , Marcel Wolbers a , Nguyen Van Vinh Chau e , Nguyen Van Kinh d , 
Guy E. Thwaites a , b , H. Rogier van Doorn a , b , Heiman F.L. Wertheim b , f 
a Oxford University Clinical Research Unit, Hanoi & Ho Chi Minh City, Viet Nam 
b Centre for Tropical Medicine & Global Health, Nuﬃeld Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom 
c Department of Infectious Diseases, Hanoi Medical University, Hanoi, Viet Nam 
d National Hospital for Tropical Diseases, Hanoi, Viet Nam 
e Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 
f Department of Medical Microbiology, RadboudUMC, Nijmegen, The Netherlands 
a r t i c l e i n f o 
Article history: 
Accepted 19 March 2019 
Available online xxx 
Keywords: 
Matrix-assisted laser desorption-ionization 
mass spectrometry 
Microbiological techniques 
Bacteraemia 
Antibacterial agents 
Vietnam 
s u m m a r y 
Objectives: We assessed the impact of MALDITOF-MS on the timeliness of optimal antimicrobial therapy 
through a parallel-arm randomised controlled trial in two hospitals in Vietnam. 
Methods: We recruited patients with a pathogen (bacterial or fungal) cultured from a normally sterile 
sample. Samples were randomly assigned (1:1) to identiﬁcation by MALDITOF-MS or conventional diag- 
nostics. The primary outcome was the proportion on optimal antimicrobial therapy within 24 h of posi- 
tive culture, determined by a blinded independent review committee. Trial registered at ClinicalTrials.gov 
(NCT02306330). 
Results: Among 1005 randomised patients, pathogens were isolated from 628 (326 intervention, 302 con- 
trol), with 377 excluded as likely contaminants or discharged/died before positive culture. Most isolates 
were cultured from blood (421/628, 67.0%). The proportion receiving optimal antimicrobial therapy within 
24 h (the primary outcome) or 48 h of growth was not signiﬁcantly different between MALDITOF-MS and 
control arms (135/326, 41.4% vs 120/302, 39.7%; Adjusted Odds ration (AOR) 1.17, p = 0.40 and 151/326, 
46.3% vs 141/302, 46.7%; AOR 1.05 p = 0.79, respectively). 
Conclusions: MALDITOF-MS, in the absence of an antimicrobial stewardship programme, did not improve 
the proportion on optimal antimicrobial therapy at 24 or 48 h after ﬁrst growth in a lower-middle income 
setting with high rates of antibiotic resistance. 
© 2019 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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High quality laboratory diagnostics play an important role
n the management of infectious diseases. 1 , 2 Low- and middle-
ncome countries (LMICs) often lack the resources for these.
he consequence is limited knowledge of bacterial epidemiol-
gy and susceptibility, exacerbating inappropriate antibiotics usen Association. This is an open access article under the CC BY license. 
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Control
N=510
MALDITOF
N=495
Analysis populaon N=302
6 unclassiﬁed:
5 Likely HAI in ICU
1 No appropriate sensivies
Total Paents Randomised:
N= 1005
169 Excluded: 
Contaminant = 153
Discharged before sample posive = 16
208 Excluded:
Contaminant = 189
Discharged before sample posive = 19
Analysis populaon N=326a
3 unclassiﬁed: 
3 Likely HAI in ICU
Fig. 1. Trial ﬂow. 
a 2 patients randomised to MALDITOF had identiﬁcation by routine methods. They 
were analysed as per their randomisation arm (i.e. included in MALDITOF group). 
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tand impacting on both antimicrobial resistance (AMR) and patient
outcomes. 
Recognising this, investment in hospital laboratory infrastruc-
ture and capacity building in LMICs has attracted international
attention. 3 –5 Eﬃcient use of limited available resources is needed
to develop optimal laboratory capacity, avoid inappropriate use
of antibiotics and improve patient outcomes. 6 Novel technologies
have been developed to improve identiﬁcation and susceptibility
testing results, but many are expensive 1 , 7 and developed in and
for high income countries 8 but are now being introduced in LMIC
laboratories. Systematic evaluation of these is important, espe-
cially in resource constrained settings, to show impact on clinical
decision-making and patient care. 
Matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry (MALDITOF-MS) accurately identiﬁes cultured bacte-
ria and fungi within minutes. 9 , 10 Whilst the hardware is expensive
(approximately 250,0 0 0 USD) it has very low per assay costs (1-1.5
USD/sample) and requires minimal skills. 9 –11 Reagents have long
expiry dates, unlike traditional biochemical identiﬁcation systems
(leading to regular use of expired reagents is common in LMICs). 12 
Thus MALDITOF-MS has potential to improve microbiological diag-
nostics in LMICs. 
Previous studies in high-income settings, where MALDITOF has
been combined with an antimicrobial stewardship programme
(ASP), have shown clinical impact on reduced time to optimal an-
tibiotic therapy, 13 , 14 increased proportion of appropriate antibiotic
treatment after culture positivity 15 and reduced length of hospital
stay. 14 , 16 –18 
To date no randomised controlled trials have been reported
exploring the beneﬁt of MALDITOF-MS compared with conven-
tional microbiology in relation to clinical endpoints, nor have there
been any studies of its clinical (as opposed to diagnostic) utility
in LMICs. We aimed to determine whether MALDITOF-MS reduced
the time to optimal antibiotic therapy compared to conventional
microbiological identiﬁcation in patients with conﬁrmed infection. 
Materials and Methods 
Study design and participants 
A parallel arm randomised controlled trial was conducted in 2
tertiary infectious diseases hospitals in Vietnam: the National Hos-
pital for Tropical Diseases (NHTD) in Hanoi and the Hospital for
Tropical Diseases (HTD) in Ho Chi Minh City. Both have ISO15189
accredited microbiology laboratories. Positive blood cultures or as-
pirates from sterile compartments (cerebrospinal ﬂuid (CSF), deep
abscesses, joint ﬂuid, peritoneal ﬂuid, pleural ﬂuid or deep tissue
biopsies) were randomised. Patients with at least one pathogenic
bacteria or fungus cultured from such samples were recruited, pa-
tients whose cultures showed contamination were not recruited
as optimal therapy for such patients would depend on the clini-
cal picture rather than the blood culture result. Patients were not
recruited if at the time of randomisation they already had an eli-
gible sample processed during the same hospital admission. 
Microbiological methods 
Clinical specimens were collected and cultured according to
standard practice. Blood culture bottles (aerobic) were incubated
for up to ﬁve days in an automated system (Bactec, Becton-
Dickinson, USA). Other samples were incubated on media allowing
growth of aerobic, anaerobic and fastidious organisms and checked
daily. Positive specimens were randomly allocated to identiﬁcation
by either MALDITOF-MS (Microﬂex LT/SH, Bruker, Germany, library
DB4613) or conventional diagnostics. For the MALDITOF-MS arm,
positive blood culture media or colonies from plates were sub-Please cite this article as: B. Nadjm, V.Q. Dat and J.I. Campbell et al., 
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Impact on optimal antimicrobial therapy of invasive bacterial and fun
1016/j.jinf.2019.03.010ultured onto blood agar until growth could be observed. (Sup-
lementary Fig. 1 ) Colonies were then analysed by MALDITOF-MS
wice daily, a result was considered positive identiﬁcation if it gave
 score ≥2.00. In the control arm, methods for identiﬁcation in-
luded: Gram-staining, API test strips, VITEK2 (bioMérieux, Marcy
’Étoile, France) and other tests as per standard operating proce-
ures. All media were commercially sourced. 
andomization and masking 
Randomisation was 1:1 by a web based randomization pro-
ram using a random variable block length of 4 or 6, with strat-
ﬁcation by hospital and specimen type (blood vs. other). When
n eligible specimen showed growth, the technician entered pa-
ient and specimen code into the randomization program. The di-
gnostic pipeline allocation was then generated and logged. All
ubsequent positive eligible specimens from that patient were as-
igned to the same arm. Patients were recruited when the sample
rew a pathogen. In HTD only this followed consent of the partic-
pant or legal representative. Samples that yielded organisms not
onsidered pathogens (e.g. coagulase-negative staphylococci, diph-
heroids, viridans group streptococci in the absence of a matching
linical syndrome) were not included. Treating physicians were not
nformed of the allocated arm. 
rocedures 
Clinical and microbiological data were collected prospectively
nto a Case Record Form (CRF) and checked for accuracy by re-
earch staff. At least 24 h following delivery of the written report
o the ward, the research team asked the clinical team if this had
hanged management and if not, why not. 
No other changes were made to routine hospital procedures
or communication of culture results to clinical teams. This in-
olved direct reporting of Gram-stains and positive culture results
y phone followed by issue of a written report through the inter-
al postal system. No antimicrobial stewardship intervention was
nvolved in the study. Hospital staff had access to a variety of in-
ernational and national guidelines. A randomised controlled trial of matrix-assisted laser desorption 
onventional microbiological methods for identifying pathogens: 
gal infections in Vietnam, Journal of Infection, https://doi.org/10. 
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l  utcomes 
The primary outcome was the proportion of patients on opti-
al antimicrobial treatment within 24 h of positive culture (ﬁrst
bserved growth of an eligible specimen). Optimal antimicrobial
reatment was deﬁned as treatment using any drug to which the
solate showed in vitro susceptibility (using AST results from the
ame agent or by proxy according to CLSI guidelines) and had
nown clinical susceptibility, but not including unnecessarily broad
pectrum regimens. The decision on optimal therapy was made
y an independent review committee, blinded to the diagnostic
rm. The committee reviewed the admission and discharge diag-
osis, the antimicrobials used during the admission and the full
icrobiology results. The committee were asked to determine the
ollowing: presence of optimal antimicrobial therapy at 24 h and
t 48 h (secondary endpoint), or at any point during hospital stay.
f therapy was not optimal at 24 h the reasons were grouped into:
oo broad, organism not covered, and ‘other’. Examples of ‘too
road therapy’ would include: use of a carbapenem for treatment
f conﬁrmed meningitis or sepsis due to Streptococcus suis or
treptococcus pneumoniae or non-ESBL producing, cephalosporin
usceptible Enterobacteriaceae ; use of a combination of ß-lactam
nd another agent for treatment of Enterobacteriaceae susceptible
o the ß-lactam etc . Inter-reviewer discrepancies were resolved by
iscussion of the case and review of international guidelines. If the
ommittee considered the organism was not the only reason for
ntimicrobial therapy a decision of ‘unclassiﬁable’ was recorded. 
tatistical analysis 
We expected the proportion of patients on optimal therapy
ithin 24 h to increase from 40% (conventional diagnostics) to 60%
MALDITOF-MS). 15 To detect this with 90% power at the 2-sided
igniﬁcance level of 5%, requires a total sample size of 260. To al-
ow suﬃcient power for a subgroup analysis in blood cultures for
ach hospital separately, the target enrolment was 280 patients re-
ruited at the slower recruiting hospital. 
The statistical analyses were predeﬁned in an analysis plan. For
he primary outcome we used a logistic regression model of the
rimary outcome depending on arm, with additional adjustment
or the ﬁrst specimen type (blood vs. other) and study site. As
 conservative measure, subjects with an ‘unclassiﬁable’ primary
utcome were labelled as ‘non-optimal’, as were subjects that were
ischarged or died within 24 h unless optimal therapy had been
tarted before death/discharge. Subgroup analyses and secondary
utcome of optimal therapy within 48 h of positive culture were
erformed in the same way as for the whole population. Analyses
ere performed using R (Version 3.4.0). P values below 0.05 were
onsidered signiﬁcant (two-sided). Further details available in sup-
lementary material (statistics analysis plan). 
thics 
Eligible patients received written information about the study,
nforming them of its purpose, procedures, their right to refuse
articipation and how to get more information or withdraw. Any
atient who requested not to be enrolled had their specimens la-
elled accordingly and diagnostics as per routine practice. 
The institutional review board (IRB) in the National Hospital
or Tropical Diseases (77/HDDD-NDTU) approved the study without
he need for individual patient consent. The IRB in the Hospital for
ropical Diseases (16-HDDD-QD) required all patients (or legal rep-
esentatives) to be seen by study staff, informed of the study, and
ive written consent before participation. The study was also ap-
roved by the Oxford Tropical Research Ethics Committee (55-14)
nd registered at ClinicalTrials.gov (NCT02306330). Please cite this article as: B. Nadjm, V.Q. Dat and J.I. Campbell et al., 
ionization-time of ﬂight mass spectrometry (MALDITOF-MS) versus c
Impact on optimal antimicrobial therapy of invasive bacterial and fun
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tudy Population 
The trial recruited between 1st December 2014 and 15th Jan-
ary 2016. The study was stopped when the sample size for the
rimary outcome was exceeded. 1005 patients with a positive ster-
le site culture were randomized. In accordance with the proto-
ol, the 342 cultured bacteria considered contaminants and the 35
rawn from patients who had either died or been discharged by
he time the culture became positive were excluded post randomi-
ation, leaving 628 patients for the analysis ( Fig. 1 ). Among the 628
amples, 421 (67.0%) were blood, 154 (24.5%) CSF, 46 (7.3%) peri-
oneal ﬂuid, 6 (1.0%) deep abscess samples, and 1 (0.2%) pleural
uid. 635 bacterial or fungal isolates were obtained (1 patient had
 isolates in a single culture and 4 patients had 2 isolates). There
ere 105 fungi, including Cryptococcus neoformans (63/635, 9.9%)
nd Talaromyces marneffei (36/635, 5.7%). There were no signiﬁcant
ifferences in baseline variables between the two arms ( Tables 1
nd 2 ). 
rimary outcome 
The proportion of patients who received optimal therapy within
4 h, was not different between MALDITOF-MS (135/326, 41.4%)
nd control arms (120/302, 39.7%) (Adjusted Odds Ratio (AOR)
.17; 95% conﬁdence interval (CI) 0.82–1.67, p = 0.40). In 9 cases
3 MALDITOF-MS, 6 control arm) the review committee recorded
herapy as ‘unclassiﬁable’ and these were included in the ‘not opti-
al’ outcome as per the analysis plan. The predominant reason for
he committee to consider a treatment non-optimal was because
herapy was too broad (254/373, 68.1%) ( Table 3 ). 
econdary outcomes 
There was no difference in the proportion of patients on op-
imal therapy within 48 h of growth between MALDITOF-MS
151/326, 46.3%) and control arms (141/302, 46.7%, AOR 1.05
 = 0.79) ( Table 4 ) or in the time from growth to optimal antimi-
robial therapy (HR 0.99 (95%CI 0.81– 1.22) p = 0.937) ( Fig. 2 ). 
There was no difference in the ordinal outcome (hospital out-
ome grouped into 5 categories - death, palliative discharge,
urvived with sequelae, transferred to another hospital and recov-
red) adjusted for site and sample type, between the MALDITOF-
S and control arms (AOR 0.869 (95%CI 0.65 – 1.16) p = 0.34). Al-
hough median hospital stay was the same for both arms, Cox pro-
ortionate hazards adjusted for site and specimen type demon-
trated an increased hazard ratio for hospital discharge in the
ALDITOF-MS arm ( Table 5 & Supplementary Fig. 2 ). Analysis
n survivors only showed similar median length of stay in the
ALDITOF-MS (15 days, IQR 11-21) and control arms (16 days, IQR
1-23). There was no signiﬁcant difference in other pre-speciﬁed
econdary outcomes ( Table 5 and Supplementary Fig. 3). 
ubgroup analyses 
Limiting the analysis to the subgroup of patients with Gram-
ositive organisms cultured showed a trend towards an increased
roportion on optimal therapy at 24 h in the MALDITOF-MS
rm (45/103, 43.7%) compared to the control arm (41/111, 36.9%;
 = 0.1). However, there was no signiﬁcant effect observed in any
re-speciﬁed subgroup analysis ( Table 6 ). 
xploratory analyses 
An analysis of mortality as a binary outcome (death or pal-
iative discharge compared with all other outcomes) adjusted forA randomised controlled trial of matrix-assisted laser desorption 
onventional microbiological methods for identifying pathogens: 
gal infections in Vietnam, Journal of Infection, https://doi.org/10. 
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Table 1 
Baseline characteristics of groups by patients. 
N MALDITOF-MS n (% or IQR) N Control n (% or IQR) P ∗
Sex 326 302 0.45 
- Female 121 (37) 103 (34) 
Age (median years) 47 (32–59) 47 (35–58) 0.91 
Site 326 302 0.57 
- Ho Chi Minh city (HCMC) 187 (57) 180 (60) 
- Hanoi 139 (43) 122 (40) 
Source 325 302 0.58 
- Direct Admission 163 (50) 144 (48) 
- Hospital transfer 162 (50) 158 (52) 
Ward 326 302 0.41 
- Critical Care 79 (24) 82 (27) 
- Other 247 (76) 220 (73) 
Site of infection 326 302 0.33 
- Central nervous system (CNS) 81 (25) 89 (29) 
- Abdominal 83 (25) 81 (27) 
- Respiratory 31 (10) 23 (8) 
- Other 40 (12) 44 (15) 
- Unknown 91 (28) 65 (22) 
ICD-10 Code 325 302 0.12 
- Sepsis 87 (27) 81 (27) 
- HIV related 69 (21) 59 (20) 
- CNS Infection 46 (14) 49 (16) 
- Cirrhosis 28 (9) 29 (10) 
- Tetanus 6 (2) 4 (1) 
- Other 89 (27) 80 (27) 
Length of illness (median days) 321 6 (3–14) 300 6 (3–14) 0.62 
Time from sample collection to ﬁrst growth (median hours) 34 (22–45) 36 (22–46) 0.41 
Time from sample collection to Gram stain (median hours) 287 31 (21–43) 267 33 (20–44) 0.63 
Specimen type 326 302 0.61 
- Blood Culture 222(68) 199 (66) 
- Other 104 (32) 103 (34) 
Pathogen type 326 302 0.40 
- Gram-positive 103 (32) 111 (37) 
Streptococcus suis 38 (12) 46 (15) 
-Gram-negative 167 (51) 137 (46) 
Escherichia coli 83 (25) 64 (21) 
- Fungi 52 (16) 52 (17) 
- Mixed 4 (1) 2 (1) 
∗ Fisher’s exact test for proportions and Kruskal–Wallis test for non-parametric data. 
Table 2 
Baseline characteristics by organisms isolated. 
N MALDITOF-MS n (%) N Control n (%) P ∗
Identiﬁcation 329 306 
Gram-negative 
Total Enterobacteriaceae 131 (40) 104 (34) 0.15 
- Escherichia Coli 83 (25) 64 (21) 
- Klebsiella pneumoniae 29 (9) 21 (7) 
- Other Enterobacteriaceae 19 (6) 19 (6) 
Total Non- Enterobacteriaceae 40 (12) 36 (12) 0.98 
- Acinetobacter & Pseudomonas spp. 14 (4) 12 (4) 
- Other Gram-negatives 26 (8) 24 (8) 
Total Gram-positive 105 (32) 114 (37) 0.18 
- Streptococci 70 (21) 85 (28) 
- Staphylococcus aureus 32 (10) 26 (8) 
- Other Gram-positives 3 (1) 3 (1) 
Total Fungi 53 (16) 52 (17) 0.85 
- Cryptococcus neoformans 29 (9) 34 (11) 
- Talaromyces marneffei 20 (7) 16 (5) 
- Other fungi 4 (1) 2 (1) 
Bacteria resistance proﬁles (where tested) 
- S. aureus with methicillin resistance 32 16 (50) 26 15 (58) 0.99 
- Enterobacteriaceae with 3G-C resistance 131 63 (48) 103 a 50 (49) 1 
- Enterobacteriaceae with carbapenem resistance 123 b 9 (7) 97 c 1 1 0.06 
- Acinetobacter or Pseudomonas species with carbapenem resistance 13 d 5 (38) 11 e 5 (45) 1 
- Enterococci with vancomycin resistance 5 1 (20) 6 2 (33) 1 
∗ Fisher’s exact test.3G- C = 3rd generation cephalosporin. 
a 1 isolate not tested ( K. pneumoniae ). 
b 8 isolates not tested ( 1 Klebsiella pneumoniae , 7 Salmonella spp.). 
c 7 isolates not tested (2 E. coli , 2 K. pneumoniae , 3 Salmonella spp.). 
d 1 isolate not tested ( Acinetobacter sp. ). 
e 1 isolate not tested ( Acinetobater baumannii ). 
Please cite this article as: B. Nadjm, V.Q. Dat and J.I. Campbell et al., A randomised controlled trial of matrix-assisted laser desorption 
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Table 3 
Reasons for non-optimal therapy at 24 h after culture growth according to the independent re- 
view committee. 
MALDITOF-MS Control 
N = 191 N = 182 
n (%) n (%) 
Pathogen not covered 54 (28.3) 46 (25.3) 
Therapy too broad 130 (68.1) 122 (67) 
Therapy potentially effective but not ideal 3 (1.6) 6 (3.3) 
Growth of second pathogen within 48 h that was not covered 1 (0.5) 2 (1.1) 
No data 3 (1.6) 6 (3.3) 
Table 4 
Proportions of patients on optimal antibiotic therapy within 24 and 48 h of growth. 
N MALDITOF-MS n (%) N Control n (%) AOR (95% CI) a p 
Within 24 h 326 135 (41.4) 302 120 (39.7) 1.17 (0.82–1.67) 0.40 
Within 48 h 326 151 (46.3) 302 141 (46.7) 1.05 (0.74–1.50) 0.79 
a Adjusted odds ratio adjusted for specimen type (blood/other) and site. 
Table 5 
Pre-speciﬁed secondary outcomes. 
N MALDITOF-MS N Control P 
DDD of antimicrobial consumption from enrolment to discharge (median, IQR) 304 16.0 (8.4–33) 283 18.0 (9.0–39.3) 0.35 a 
Days of antimicrobial therapy from enrolment to discharge (median, IQR) 304 10 (6–15) 282 11 (7–17.8) 0.287 b 
Days in hospital (Median, IQR) 322 15 (10–21) 301 16 (10–23) 0.039 c 
Days spent in Critical Care (Median, IQR) 115 5 (2–11) 100 4 (3–10.3) 0.38 d 
Hours from ﬁrst growth to pathogen identiﬁcation (Median, IQR) 324 2.2 (1.7–28.1) 298 26.6 (24.7–48) ND 
Hours from sample collection to pathogen identiﬁcation (Median, IQR) 324 43.2 (28.1–69.1) 298 66 (48–88.6) ND 
Days from sample collection to hospital discharge (Median, IQR) 326 11 (6.1–16.3) 302 12.3 (7.2–19) ND 
a Linear regression coeﬃcient 0.92 (95% CI 0.78–1.09) after adjustment for site and specimen type. 
b Hazard ratio for stopping antibiotics 1.09 (95% CI 0.92–1.29) after adjustment for site and specimen type. 
c Hazard ratio for hospital discharge 1.18 (95% CI 1.01–1.38) after adjustment for site and specimen type. 
d Hazard ratio for ICU discharge 1.13 (95% CI 0.86–1.49) after adjustment for site and specimen type in those that had an ICU stayND statistical 
comparison not performed (as stipulated in the analysis plan). 
Table 6 
Pre-speciﬁed subgroup analyses of proportion of patients on optimal therapy within 24 and 48 h of culture growth in predeﬁned subgroups. 
Proportion optimal within 24 h of culture growth Proportion optimal within 48 h of culture growth 
N MALDITOF n (%) N Control n (%) AOR (95% CI) a P N MALDITOF n (%) N Control n (%) AOR (95% CI) a P 
Sample Type 0.43 b 0.58 b 
- Blood 222 75 (33.8) 199 59 (29.6) 1.31 (0.84–2.07) 0.23 222 88 (39.6) 199 76 (38.2) 1.14 (0.73–1.78) 0.56 
- Other 104 60 (57.7) 103 61 (59.2) 0.96 (0.53–1.72) 0.88 104 63 (60.6) 103 65 (63.1) 0.91 (0.50–1.65) 0.75 
Site 0.60 b 0.98 b 
- HCMC 187 108 (57.8) 180 101 (56.1) 1.09 (0.72–1.67) 0.68 187 122 (65.2) 180 116 (64.4) 1.05 (0.68–1.62) 0.83 
- Hanoi 139 27 (19.4) 122 19 (15.6) 1.38 (0.71–2.74) 0.34 139 29 (20.9) 122 25 (20.5) 1.06 (0.57–1.99) 0.86 
Pathogen type 0.61 b 0.51 b 
- Gram-positive 103 45 (43.7) 111 41 (36.9) 1.74 (0.90–3.42) 0.10 103 47 (45.6) 111 47 (42.3) 1.42 (0.74–2.74) 0.30 
- Gram-negative 167 58 (34.7) 137 47 (34.3) 1.09 (0.65–1.82) 0.75 167 70 (41.9) 137 62 (45.3) 0.91 (0.55–1.52) 0.72 
- Fungi 52 31 (59.6) 52 32 (61.5) 1.09 (0.41–3.01) 0.86 52 33 (63.5) 52 32 (61.5) 1.38 (0.52–3.70) 0.53 
Admitted from 0.90 b 0.72 b 
- Home 163 71 (43.6) 144 61 (42.4) 1.17 (0.72–1.90) 0.53 163 80 (49.1) 144 71 (49.3) 1.10 (0.68–1.79) 0.70 
- Hospital 162 64 (39.5) 159 59 (37.3) 1.16 (0.68–1.99) 0.59 162 71 (43.8) 158 70 (44.3) 0.99 (0.58–1.69) 0.97 
Final diagnosis 0.73 b 0.76 b 
- Meningitis 76 57 (75.0) 65 48 (73.8) 1.28 (0.56–3.00) 0.56 76 59 (77.6) 65 51 (78.5) 1.11 (0.46–2.66) 0.81 
- Other 250 78 (31.2) 237 72 (30.4) 1.07 (0.71–1.63) 0.74 250 92 (36.8) 237 90 (38.0) 0.96 (0.64–1.45) 0.86 
a Adjusted for site and specimen type except where these are part of the subgroup. 
b Test for heterogeneity. 
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n  ite and sample type revealed no difference (MALDITOF-MS arm
2/326 (16.0%), control arm 43/302 (14.2%), AOR 1.13 (95%CI 0.73–
.76, p = 0.59)). 
Excluding outliers (the longest staying 1% of patients) in an
nalysis of hospital stay to explain the increased hazards ratio for
ospital discharge in the MALDITOF-MS arm, the hazard ratio for
ischarge in the MALDITOF-MS arm dropped to 1.16 ( p = 0.067). 
An analysis to determine whether results were reaching the
ards more quickly in the MALDITOF-MS arm demonstrated that
he median time from growth to the pathogen identiﬁcation re-Please cite this article as: B. Nadjm, V.Q. Dat and J.I. Campbell et al., 
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1016/j.jinf.2019.03.010ort being received on the ward was 10.1 h (IQR 1.9 – 32.9 h) in
he MALDITOF-MS arm and 31.0 h (IQR 27.4–54 h) in the control
rm. 
A subgroup analysis of the 146 patients not on optimal ther-
py at the time of culture growth, that subsequently did receive
ptimal therapy, showed that the median time to optimal therapy
as 2.0 (IQR 0.7–5.6) days in the MALDITOF-MS arm and 2.6 (IQR
.2 – 4.8) days in the control arm. A further subgroup analysis of
hose patients according to whether they were in critical care or
ot when cultures were drawn showed no signiﬁcant difference inA randomised controlled trial of matrix-assisted laser desorption 
onventional microbiological methods for identifying pathogens: 
gal infections in Vietnam, Journal of Infection, https://doi.org/10. 
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Fig. 2. Time from growth to optimal antimicrobial therapy (OAT). 
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w  both those in critical care (OR 0.90 (95% CI 0.5 – 1.72, p = 0.81)) or
other wards (OR 1.16 (95%CI 0.79–1.69, p = 0.45)). 
An analysis looking at the proportion receiving antibiotic ther-
apy at 24 h after culture growth that lacked in vitro activity against
the isolated pathogen (inadequate therapy) showed little differ-
ence between the two arms (54/326, 16.6% and 46/302, 15.2% in
MALDITOF-MS and control arms respectively). 
Discussion 
Our study demonstrates that early identiﬁcation of pathogens
from cultures of blood and other sterile sites using MALDITOF-MS
did not result in a difference in the proportion of patients on opti-
mal therapy within 24 h of ﬁrst growth. Neither did MALDITOF-MS
alter the proportion on optimal therapy by 48 h, the time taken to
provide optimal therapy, the duration or total antibiotic therapy,
patient outcomes or time in intensive care. We found an associa-
tion between MALDITOF-MS and earlier hospital discharge, but the
signiﬁcance was removed when outliers were excluded (very long
stay patients) and we consider it unlikely to be clinically signiﬁ-
cant. Ours is not the ﬁrst study to demonstrate that technological
advances in rapid diagnostics, though compelling, do not always
lead to improvements in clinically relevant outcomes in the ab-
sence of an antibiotic stewardship programme. A similar result was
found in a randomized study of the impact of peptide nucleic acid
ﬂuorescence in situ hybridisaton (PNA-FISH) on a variety of clinical
outcomes in a tertiary care hospital in the USA. 19 
In common with previous studies, we found quicker pathogen
identiﬁcation and reporting. Our study gives some indication as to
why MALDITOF-MS results did not result in improved outcomes.
In both arms Gram stain results for positive blood cultures were
available rapidly and possibly already provided suﬃcient informa-
tion. The most common cause of suboptimal therapy was use of
excessively broad therapies, suggesting that there were delays or
reluctance in de-escalation of therapy. There was some evidencePlease cite this article as: B. Nadjm, V.Q. Dat and J.I. Campbell et al., 
ionization-time of ﬂight mass spectrometry (MALDITOF-MS) versus c
Impact on optimal antimicrobial therapy of invasive bacterial and fun
1016/j.jinf.2019.03.010hat the intervention was more successful in patients with Gram-
ositive infections. This may relate to identifying Streptococcus suis ,
 common cause of both meningitis and severe sepsis which has as
et not evolved reduced susceptibility to penicillin 20 and exclusion
f alternative pathogens. 
One other trial of MALDITOF-MS compared with conventional
icrobiology with 28 day mortality as the primary endpoint has
ompleted recruitment in the UK but has yet to be reported (the
APIDO trial, https://doi.org/10.1186/ISRCTN97107018 ). While other
tudies have established that MALDITOF-MS can identify pathogens
n the tropics, 21 all eight publications that explored the clinical im-
act of MALDITOF-MS 13 –18 , 22 , 23 were conducted in high income
ountries (HICs). Three explored the impact of MALDITOF-MS com-
ared with conventional diagnostics 15 , 16 , 22 without an ASP compo-
ent. One was restricted to peritoneal dialysis ﬂuid, 16 the others
ecruited patients with bloodstream infections. 15 , 22 One showed a
igniﬁcant improvement in the proportion with appropriate ther-
py within 24 h of growth (from 64% to 75.3%, p = 0.01), 15 while
he other found a non-signiﬁcant improvement in the proportion
eceiving active treatments within 48 h of blood cultures being
from 89.8% to 95.6%, p = 0.09). 22 Five studies examined the impact
f MALDITOF-MS plus ASP with conventional diagnostics without
SP. 13 , 14 , 17 , 18 , 23 These studies all showed improvements in time to
ctive or appropriate therapy and two showed lower mortality. 13 , 14 
Our study has the advantage of addressing the single interven-
ion of MALDITOF-MS, highlighting the need to investigate addi-
ional supports, such as ASP, to achieve clinical impact. It cannot
e generalized to settings where ASP are already in place. The in-
ividually randomised nature of the study is robust but this design
ay not account for changes in prescribing that could arise from
 ‘cultural shift’ resultant from a wholesale change in diagnostic
ractice. Although the use of two sites and the large sample size is
 strength, the use of specialist infectious diseases hospitals could
ause bias and poor generalisability. However, it seems unlikely
hat MALDITOF-MS alone would be more effective at changing pre-
cribing practice in a setting where staff are less experienced in
anaging infection and the uniformity of the results across differ-
nt pathogen groups makes it unlikely that the case mix seen is
esponsible for the negative results. There may be criticism over
he subjectivity of the primary endpoint (optimal therapy as deter-
ined by a panel of experts) and others have utilized spectrum-of-
ctivity scores to demonstrate improvements in de-escalation. 24 , 25 
owever, the blinded nature of the committee, and the use of a
ingle committee for all evaluations, should have minimized bias.
dditionally, the absence of beneﬁt in the comparison of the pro-
ortion receiving inadequate therapy in the two arms at 24 h sug-
ests that the ﬁndings were real. We did not collect data on pa-
ient severity (SOFA/APACHE II scores), making it diﬃcult to assess
hether a subgroup of either more or less severe patients may
ave seen beneﬁt from the intervention. However an exploratory
nalysis showed no effect of the intervention in patients that were
n critical care at the time cultures were drawn. Our study did not
chieve the prespeciﬁed sample size. However, this large sample
ize was determined to accurately assess if the intervention was
ffective for blood cultures in each hospital, we surpassed the sam-
le size necessary for the primary outcome and it is thus unlikely
e missed a relevant positive result. Our setting has particularly
igh proportions of antibiotic resistant organisms, and results may
ot be generalisable to settings where these are lower. Although
he contamination rate was noted to be high during the study, it is
ot outside that reported in the literature. 26 Attempts were made
o reduce the contamination rate through additional education for
hose responsible for venepuncture, and replacement of liquid dis-
nfection ﬂuids with disposable sterile alcohol wipes. There was
 small number of cases where the endpoint review committee
as unable to reach a decision (6 in the control arm and 3 in theA randomised controlled trial of matrix-assisted laser desorption 
onventional microbiological methods for identifying pathogens: 
gal infections in Vietnam, Journal of Infection, https://doi.org/10. 
B. Nadjm, V.Q. Dat and J.I. Campbell et al. / Journal of Infection xxx (xxxx) xxx 7 
ARTICLE IN PRESS 
JID: YJINF [m5G; April 3, 2019;13:23 ] 
M  
s
 
p  
s  
d  
a  
d  
p  
w  
A  
a  
i  
s  
f
 
c  
t  
r  
p  
t  
s  
n
A
 
v  
t  
 
l  
W
a  
O  
a
S
 
f
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2  
 
 
 
 
2  
 
 
2  
 
 
2  
 
 
2  
 
 
2  
 
 
2  
 ALDITOF-MS arm), these results could not have changed the re-
ult of the primary outcome (data not shown). 
Despite these negative ﬁndings there are several positive as-
ects to MALDITOF-MS that should not be overlooked. Firstly, even
peedier identiﬁcation can be achieved by both processing samples
irect from blood culture 27 (without the subculture onto blood
gar) and by running the machine more frequently than twice
aily. However, this requires changes to work ﬂow that were not
ossible within the trial and, based on the results we obtained,
ould be unlikely to have had an impact on the results. Rapid
ST, either through short incubation with antibiotics or through
nalysis of the spectra obtained, has also now been described us-
ng MALDITOF-MS. 28 Though more technically diﬃcult, such re-
ults may have been more compelling in this setting and warrant
urther evaluation. 
In conclusion, our study showed no improvement in antimi-
robial prescribing or other patient or provider centred outcomes
hrough MALDITOF-MS, though MALDITOF-MS did produce results
apidly in our setting. While MALDITOF-MS has many other com-
elling advantages, our ﬁndings suggest that it is unlikely to lead
o improvements in prescribing on its own. Further studies in this
etting exploring the addition of ASPs, and education of the diag-
ostic and prescribing workforce would be useful. 
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